Survival of patients with distal esophageal and gastric cardia tumors: A population- based analysis of gastroesophageal junction carcinomas Bryan A. Whitson,

Slides:

Advertisements

Similar presentations

Manuel J. Antunes, MD, PhD, DSc

Advertisements

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma Kimberly S. Grant, MD,

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Stephen R. Broderick, MD, MPHS

A wolf in sheep's clothing

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the.

Do tumor location and grade affect survival in pT2N0M0 esophageal squamous cell carcinoma? Dongrong Situ, MD, Junye Wang, MD, PhD, Peng Lin, MD, PhD,

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Lung cancer screening: No more excuses

The days of future past Neel K. Ranganath, MD, Aubrey C. Galloway, MD

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Jennifer Chung, MD, MSc, Maral Ouzounian, MD, PhD

Intrinsic cardiac stem cells are essential for regeneration

Accounting for outcomes: Lies, damned lies, and statistics

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Multilevel data analysis: What? Why? How?

Basic and translational research careers as early faculty cardiothoracic surgeons— perspectives from 2 young investigators Keshava Rajagopal, MD, PhD,

Go on-pump or off-pump in diabetic patients?

Lymph node involvement in advanced gastroesophageal junction adenocarcinoma Corrado Pedrazzani, MD, Giovanni de Manzoni, MD, Daniele Marrelli, MD, Simone.

Shawn S. Groth, MD, Bryan M. Burt, MD

The lord of the rings Antonio Miceli, MD, PhD

Invasive adenocarcinoma with bronchoalveolar features: A population-based evaluation of the extent of resection in bronchoalveolar cell carcinoma Bryan.

Survival After Lobectomy Versus Segmentectomy for Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis Bryan A. Whitson, MD, PhD, Shawn S.

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Gastric conduit revision after esophagectomy: The raising of Lazarus

Conduit conundrum: If not two, why three?

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Supraclavicular node metastasis from thoracic esophageal carcinoma: A surgical series from a Japanese multi-institutional nationwide registry of esophageal.

Does the degree of preoperative mitral regurgitation predict survival or the need for mitral valve repair or replacement in patients with anomalous origin.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

It's not “just a shunt” but sometimes it should be…

Do we need a bibliometrician to know which way the wind is blowing?

A first start for lung transplantation?

Stephen R. Broderick, MD, MPHS

Shawn S. Groth, MD, MS, R. Taylor Ripley, MD, Bryan M. Burt, MD

Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology.

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

The Ross procedure: Time to reevaluate the guidelines

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Pathologic complete response after esophagectomy following neoadjuvant chemoradiation therapy for esophageal carcinoma: A cure sometimes? Shawn S. Groth,

We are the company we keep: The importance of the tumor microenvironment Sai Yendamuri, MD, FACS The Journal of Thoracic and Cardiovascular Surgery

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Carcinoma of the esophagus: Prognostic significance of histologic type

Prognosis and “granularity”: Building on staging foundations?

Saving the esophagus: At what cost?

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma Kimberly S. Grant, MD,

The harder one looks, the more one finds

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Jeffrey H. Shuhaiber, MD, Jeff Moore, MS, David B. Dyke, MD

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Ventricular assistant in restrictive cardiomyopathy: Making the right connection Robert D.B. Jaquiss, MD The Journal of Thoracic and Cardiovascular Surgery

Spot the mesh: Six-month follow-up

Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement Todd M. Dewey,

“The more things change…”: The challenges ahead

Managing conflicts of interest

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

The evolution of cardiothoracic critical care

Of mice and men… The Journal of Thoracic and Cardiovascular Surgery

Did you like Terminator 3 better than Terminator 2

How do we follow up our patients

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Presentation transcript:

Survival of patients with distal esophageal and gastric cardia tumors: A population- based analysis of gastroesophageal junction carcinomas Bryan A. Whitson, MD, PhD, Shawn S. Groth, MD, Zhongze Li, MS, Robert A. Kratzke, MD, Michael A. Maddaus, MD The Journal of Thoracic and Cardiovascular Surgery Volume 139, Issue 1, Pages 43-48 (January 2010) DOI: 10.1016/j.jtcvs.2009.04.011 Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Cancer-specific survival of patients with midthoracic esophageal, distal esophageal, gastric cardia, and gastric body or fundus tumors (P <.0001, log-rank test; A), as well as those of the gastroesophageal junction, distal esophageal, and gastric cardia (P = .13, log-rank test; B), for all stages by using the Kaplan–Meier method. In the table along the abscissa, for each location on the far left, the 3 rows correspond with the number at risk, the proportion surviving at that time point, and the corresponding 95% confidence interval at that time point. MT, Midthoracic esophagus; DE, distal esophagus; GC, gastric cardia; GBF, gastric body or fundus. The Journal of Thoracic and Cardiovascular Surgery 2010 139, 43-48DOI: (10.1016/j.jtcvs.2009.04.011) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Cancer-specific survival, determined by using the Kaplan–Meier method, of patients with gastroesophageal adenocarcinomas for all stages in aggregate (P = .28, log-rank test; A) and for stage I (P = .27, log-rank test; B), stage II (P = .94, log-rank test; C), stage III (P = .02, log-rank test; D), and stage IV (P = .45, log-rank test; E). In the table along the abscissa, for each location on the far left, the 3 rows correspond with the number at risk, the proportion surviving at that time point, and the corresponding 95% confidence interval at that time point. DE, Distal esophagus; GC, gastric cardia. The Journal of Thoracic and Cardiovascular Surgery 2010 139, 43-48DOI: (10.1016/j.jtcvs.2009.04.011) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions